Board of Directors

BioProtection Systems/NewLink Genetics Corp
Dr. Monath is a Chief Science Officer and Chief Operating Officer of BioProtection Systems/NewLink Genetics Corp (NASDAQ: NLNK), where he is engaged in development of Ebola vaccine and new vaccines against other infectious diseases.  In his current position he is responsible for the development of the recombinant vesicular stomatitis-Ebola vaccine that has recently shown 100% efficacy in a Phase 3 trial in Guinea. The vaccine is exclusively licensed from NewLink to Merck. Monath’s expertise and experience cut across discovery research, process and analytical development, manufacturing, preclinical and clinical development, and regulatory affairs. Monath is also a Venture Partner at Kleiner Perkins Caufield & Byers and is a Director of Vaxinnate Inc., Sentinext plc, Rapid Micro Biosystems Inc, and US Biologics Inc.

Between 1992-2012 he was Adjunct Professor, Harvard School of Public Health. Between 1992 and 2006, Dr Monath was Chief Scientific Officer and an Executive Director, Acambis Inc. (a publicly traded biopharmaceutical company recently acquired by Sanofi Pasteur) where he pioneered the development of ChimeriVax® vaccines against dengue, West Nile, and Japanese encephalitis (using yellow fever as a live vector) , vaccines against yellow fever, Clostridium difficile, and Helicobacter pylori, as well as a cell based smallpox vaccine, ACAM2000 which has now replaced calf lymph vaccine in the US national stockpile.  The JE vaccine (IMOJEV®) is licensed in multiple countries; the West Nile vaccine (Prevenile®) is licensed for use in horses; and the dengue and C. difficile vaccines are in Phase III trials.   

Dr Monath received his undergraduate degree and M.D. from Harvard and trained in internal medicine at the Peter Bent Brigham Hospital, Boston. COL Monath retired from the US Army in 1992 after 24 years in the uniformed services (Army and US Public Health Service). Between 1973-1988, he was Director, Division of Vector-Borne Viral Diseases, Centers for Disease Control (CDC), Fort Collins CO and from 1989-92 Chief, Virology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID). He has worked overseas in Nigeria, Sierra Leone, Cameroun, Argentina, Ecuador and elsewhere doing field research on arboviruses and hemorrhagic fevers. In 1972, he discovered the rodent reservoir of Lassa fever virus.  He is on the editorial board of 5 scientific journals. He received the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), and the Walter Reed Medal (2002) from the American Society of Tropical Medicine & Hygiene and was President of that Society (2004-05). He has served on numerous government and international committees on infectious diseases, biosecurity, World Health Organization expert committees and the National Vaccines Advisory Committee (USA). From 1998-2000, Monath was Senior Science advisor to the Director, Central Intelligence Agency. He has been a leader in the One Health Initiative, an effort to integrate medical and veterinary disciplines in public health.  Dr. Monath has published 425 papers and 6 books on the epidemiology, immunology and pathogenesis of arboviruses and on vaccine development.

Dr Ganesh Kishore
Malaysian Life Sciences Capital Fund (MLSCF) - Chairman

Dr Zainul Zainuddin
Malaysian Technology Development Corporation (MTDC)

Amir Azahar
Elixir Capital

Naser Jaafar
Agensi Inovasi Malaysia (AIM)

Dr Uwe Schlokat
CEO & Director

about me